BlackRock
CTXR icon

BlackRock’s Citius Pharmaceuticals CTXR Stock Holding History

BlackRock’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.2K Sell
69,850
-1
-0% -$1 ﹤0.01% 5225
2026
Q1 		$62.9K Hold
69,851
– – ﹤0.01% 5070
2025
Q4 		$54.3K Hold
69,851
– – ﹤0.01% 5035
2025
Q3 		$86.6K Hold
69,851
– – ﹤0.01% 4862
2025
Q2 		$111K Sell
69,851
-2,376
-3% -$2.18K ﹤0.01% 4819
2025
Q1 		$108K Hold
72,227
– – ﹤0.01% 4750
2024
Q4 		$289K Sell
72,227
-2
-0% -$13 ﹤0.01% 4550
2024
Q3 		$904K Hold
72,229
– – ﹤0.01% 4197
2024
Q2 		$1.05M Sell
72,229
-276,831
-79% -$4.96M ﹤0.01% 4165
2024
Q1 		$7.83M Buy
349,060
+10,747
+3% +$196K ﹤0.01% 3477
2023
Q4 		$6.4M Buy
338,313
+26,867
+9% +$510K ﹤0.01% 3590
2023
Q3 		$5.33M Sell
311,446
-11,723
-4% -$279K ﹤0.01% 3629
2023
Q2 		$9.7M Buy
323,169
+229,589
+245% +$7.56M ﹤0.01% 3433
2023
Q1 		$2.74M Buy
93,580
+194
+0.2% +$5.59K ﹤0.01% 3902
2022
Q4 		$1.84M Buy
93,386
+102
+0.1% +$2.78K ﹤0.01% 4168
2022
Q3 		$2.82M Sell
93,284
-608
-0.6% -$16.7K ﹤0.01% 4016
2022
Q2 		$2.16M Sell
93,892
-229,395
-71% -$6.29M ﹤0.01% 4224
2022
Q1 		$14.5M Sell
323,287
-1,843
-0.6% -$72.8K ﹤0.01% 3374
2021
Q4 		$12.5M Sell
325,130
-1,192
-0.4% -$54.1K ﹤0.01% 3536
2021
Q3 		$16.6M Buy
326,322
+1,341
+0.4% +$67.3K ﹤0.01% 3409
2021
Q2 		$28.3M Buy
324,981
+247,835
+321% +$14.9M ﹤0.01% 3082
2021
Q1 		$3.43M Buy
+77,146
New +$3.07M ﹤0.01% 4102

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
BW
BostonPremier Wealth Hanover, Massachusetts $235M AUM 31.01% 1-Year Est. Return

BlackRock's CTXR Position: Q2 2026 in Review

BlackRock reduced its Citius Pharmaceuticals (CTXR) stake by 0% in Q2 2026, selling an estimated $1 and leaving 69,850 shares worth $42.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5225.

BlackRock first reported a position in CTXR in Q1 2021 and has held it in 22 quarters since. The position peaked at $28.3M in Q2 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • BlackRock held 69,850 shares of Citius Pharmaceuticals worth $42.2K as of Q2 2026.
  • BlackRock sold 1 Citius Pharmaceuticals share in Q2 2026, an estimated $1.
  • Citius Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5225 holding.
  • BlackRock first reported a position in Citius Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • BlackRock's Citius Pharmaceuticals position peaked at $28.3M in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.